1
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 2023; 41:3965-3972. [PMID: 37586209 DOI: 10.1200/jco.22.02764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/18/2023] Open
Abstract
PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001). CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.
Collapse
|
2
|
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2014; 25:2230-2236. [PMID: 25081901 DOI: 10.1093/annonc/mdu367] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND A germline mutation in the 3'-untranslated region of KRAS (rs61764370, KRAS-variant: TG/GG) has previously been associated with altered patient outcome and drug resistance/sensitivity in various cancers. We examined the prognostic and predictive significance of this variant in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS We conducted a retrospective study of 103 HNSCCs collected from three completed clinical trials. KRAS-variant genotyping was conducted for these samples and 8 HNSCC cell lines. p16 expression was determined in a subset of 26 oropharynx tumors by immunohistochemistry. Microarray analysis was also utilized to elucidate differentially expressed genes between KRAS-variant and non-variant tumors. Drug sensitivity in cell lines was evaluated to confirm clinical findings. RESULTS KRAS-variant status was determined in 95/103 (92%) of the HNSCC tumor samples and the allelic frequency of TG/GG was 32% (30/95). Three of the HNSCC cell lines (3/8) studied had the KRAS-variant. No association between KRAS-variant status and p16 expression was observed in the oropharynx subset (Fisher's exact test, P = 1.0). With respect to patient outcome, patients with the KRAS-variant had poor progression-free survival when treated with cisplatin (log-rank P = 0.002). Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04). CONCLUSIONS The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients. CLINICAL TRIAL REGISTRATION NUMBERS NCT00503997, NCT00425750, NCT00003809.
Collapse
Affiliation(s)
- C H Chung
- Department of Oncology; Department of Otolaryngology-Head and Neck Surgery, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore.
| | - J W Lee
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston
| | | | | | | | | | | | | | - J Gilbert
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Nashville
| | - B A Murphy
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Nashville
| | - S Nallur
- Department of Therapeutic Radiology
| | | | - R C Jordan
- Department of Pathology, University of California, San Francisco
| | | | - B Burtness
- Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven
| | | | - J B Weidhaas
- Department of Therapeutic Radiology; Department of Radiation Oncology, University of California, Los Angeles
| |
Collapse
|
3
|
Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol 2014; 25:2036-2041. [PMID: 25009013 DOI: 10.1093/annonc/mdu248] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND E2303 evaluated cetuximab, paclitaxel, and carboplatin used as induction therapy and concomitant with radiation therapy in patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) determining pathologic complete response (CR), event-free survival (EFS), and toxicity. PATIENTS AND METHODS Patients with resectable stage III/IV HNSCC underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, patients completed CRT (68-72 Gy); otherwise, resection was carried out. p16 protein expression status was correlated with response/survival. RESULTS Seventy-four patients were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no tumor (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible patients completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 patients (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 patients (8%). There were no treatment-related deaths. Toxicity was primarily hematologic or radiation-related. p16 AQUA score was not associated with response/survival. CONCLUSIONS Induction cetuximab, paclitaxel, and carboplatin followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER NCT 00089297.
Collapse
Affiliation(s)
- H J Wanebo
- Department of Surgery, Landmark Medical Center, Woonsocket.
| | - J Lee
- Department of Biostatistics & Computational Biology, Dana Farber Cancer Institute, Boston
| | - B A Burtness
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia
| | - J A Ridge
- Department of Surgery, Fox Chase Cancer Center, Philadelphia
| | - M Ghebremichael
- Department of Biostatistics & Computational Biology, Dana Farber Cancer Institute, Boston
| | - S A Spencer
- Department of Radiation Oncology, University of Alabama, Birmingham
| | - D Psyrri
- Department of Medicine, Yale University, New Haven
| | - E Pectasides
- Department of Medicine, Yale University, New Haven
| | - D Rimm
- Department of Medicine, Yale University, New Haven
| | - F R Rosen
- Department of Medical Oncology, John H. Stroger Hospital of Cook County, Chicago
| | - M R Hancock
- Department of Medical Oncology, Porter Memorial Hospital, Denver
| | - K A Tolba
- Department of Medicine, University of Miami, Miami
| | - A A Forastiere
- Department of Medical Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
| |
Collapse
|
4
|
Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 2014; 25:1410-1416. [PMID: 24799460 PMCID: PMC4071756 DOI: 10.1093/annonc/mdu167] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Revised: 03/27/2014] [Accepted: 04/16/2014] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The purpose of this article was to study the association of human papillomavirus (HPV) with clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS Archival baseline tumor specimens were obtained from patients treated on two clinical trials in recurrent or metastatic SCCHN: E1395, a phase III trial of cisplatin and paclitaxel versus cisplatin and 5-fluorouracil, and E3301, a phase II trial of irinotecan and docetaxel. HPV DNA was detected by in situ hybridization (ISH) with a wide-spectrum probe. p16 status was evaluated by immunohistochemistry. Clinical outcomes of interest were objective response, progression-free survival (PFS) and overall survival (OS). RESULTS We analyzed 64 patients for HPV ISH and 65 for p16. Eleven tumors (17%) were HPV+, 12 (18%) were p16+, whereas 52 (80%) were both HPV- and p16-. The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057). The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027). After adjusting for other covariates, hazard ratio for OS was 2.69 (P = 0.048) and 2.17 (P = 0.10), favoring HPV-positive and p16-positive patients, respectively. The other unfavorable risk factor for OS was loss of ≥5% weight in previous 6 months (P = 0.0021 and 0.023 for HPV and p16 models, respectively). CONCLUSION HPV is a favorable prognostic factor in recurrent or metastatic SCCHN that should be considered in the design of clinical trials in this setting. CLINICAL TRIAL IDENTIFIER NCT01487733 Clinicaltrials.gov.
Collapse
Affiliation(s)
- A Argiris
- Division of Hematology/Oncology Cancer Therapy and Research Center, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio.
| | - S Li
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston
| | - M Ghebremichael
- Ragon Institute of Harvard, MIT and MGH and Harvard Medical School, Boston
| | | | - L Wang
- Department of Pathology, University of Pittsburgh, Pittsburgh
| | - A A Forastiere
- Department of Medical Oncology, Johns Hopkins University, Baltimore
| | - B Burtness
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
| | - R Mehra
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
| |
Collapse
|
5
|
Psyrri A, Ghebremichael MS, Pectasides E, Dimou AT, Burtness B, Rimm D, Wanebo HJ, Forastiere AA. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Agbahiwe HC, Marur S, Forastiere AA, Sanguineti G. Lymph node density and response to induction TPF in patients with HPV-related head and neck cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5576] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 2011; 68:863-70. [PMID: 21286719 DOI: 10.1007/s00280-011-1556-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2010] [Accepted: 01/11/2011] [Indexed: 12/20/2022]
Abstract
PURPOSE Germline genetic variations may partly explain the clinical observation that normal tissue tolerance to radiochemotherapy varies by individual. Our objective was to evaluate the association between single-nucleotide polymorphisms (SNPs) in radiation/platinum pathways and serious treatment-related toxicity in subjects with esophageal adenocarcinoma who received cisplatin-based preoperative radiochemotherapy. METHODS In a multicenter clinical trial (E1201), 81 eligible treatment-naïve subjects with resectable esophageal adenocarcinoma received cisplatin-based chemotherapy concurrent with radiotherapy, with planned subsequent surgical resection. Toxicity endpoints were defined as grade ≥3 radiation-related or myelosuppressive events probably or definitely related to therapy, occurring during or up to 6 weeks following the completion of radiochemotherapy. SNPs were analyzed in 60 subjects in pathways related to nucleotide/base excision- or double stranded break repair, or platinum influx, efflux, or detoxification. RESULTS Grade ≥3 radiation-related toxicity (mostly dysphagia) and myelosuppression occurred in 18 and 33% of subjects, respectively. The variant alleles of the XRCC2 5' flanking SNP (detected in 28% of subjects) and of GST-Pi Ile-105-Val (detected in 65% of subjects) were each associated with higher odds of serious radiation-related toxicity compared to the major allele homozygote (47% vs. 9%, and 31% vs. 0%, respectively; P = 0.005). No SNP was associated with myelosuppression. CONCLUSIONS This novel finding in a well-characterized cohort with robust endpoint data supports further investigation of XRCC2 and GST-Pi as potential predictors of radiation toxicity.
Collapse
Affiliation(s)
- H H Yoon
- Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Wanebo HJ, Ghebremichael MS, Burtness B, Ridge JA, Spencer S, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5513] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Egloff AM, Lee J, Vaezi AE, Langer CJ, Forastiere AA, Quon H, Burtness B, Grandis JR. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Juergens RA, Gibson MK, Yang SC, Brock M, Heitmiller R, Tsottles N, Rudek MA, Canto M, Kleinberg L, Forastiere AA. Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Atasoy A, Yoon H, Egloff AM, Ferris RL, Zaidi AH, Hough B, Forastiere AA, Jobe BA, Nason KS, Gibson MK. Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Marur S, Forastiere AA. Update on role of chemotherapy in head and neck squamous cell cancer. Indian J Surg Oncol 2010; 1:85-95. [PMID: 22930623 PMCID: PMC3421005 DOI: 10.1007/s13193-010-0021-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2009] [Accepted: 06/07/2010] [Indexed: 12/31/2022] Open
Abstract
Head and neck squamous cell cancer (HNSCC) is most commonly a tobacco-related disease, affecting nearly 600,000 people worldwide each year. For decades, HNSCC has been treated successfully with multimodality treatments including, surgery, radiation, and chemotherapy, though the 'perfect' treatment paradigm remains elusive. This review will discuss a number of clinical trials, comparing various combinations of chemotherapy and the settings in which they are most successful. Promising research and recent data on the combination of cytotoxic chemotherapy with new biological agents indicate chemotherapy plays a critical role in treatment of HNSCC and will only continue to improve.
Collapse
Affiliation(s)
- S. Marur
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein CRB1 G92 1650 Orleans Street, Baltimore, MD 21231-1000 USA
| | - A. A. Forastiere
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein CRB1 G92 1650 Orleans Street, Baltimore, MD 21231-1000 USA
| |
Collapse
|
13
|
Yoon HH, Powell M, Murphy K, Montgomery EA, Hafez MJ, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4530 Background: EAC has eluded cure even with platin-based CRT. Stratifying pts by likelihood of success is one approach to improving outcomes. We assessed whether SNPs in DNA repair paths are associated with complete pathologic response (pCR) in EAC pts who received C-based CRT followed by surgery. Methods: Patients and specimens: Pretreatment biopsy or post-CRT resection samples were obtained from pts (EAC, stage II-IVa) treated on a randomized phase II trial, E1201 (n=86), of preop CRT (RT to 45 Gy). Arm A: Preop C 30 mg/m2 + irinotecan (I) 50 mg/m2 days (d) 1, 8, 22, 29 with RT. Post-op C 30 mg/m2 + I 65 mg/m2 d 1, 8 q21 days x 3. Arm B: Preop C 30 mg/m2 + paclitaxel (P) 50 mg/m2 d 1, 8, 15, 22, 29 with RT. Post-op C 75 mg/m2 + P 175 mg/m2 d 1 q21 days x 3. Clinical outcome - pCR: (A) 14% [95% CI 5.5%, 28.5%]; (B) 16% [95% CI 6.7%, 30.1%]. Median overall survival (OS): (A) 34.9 m (months) [90% CI 23.5, not reached]; (B) 20.9 m [90% CI 17.4, 46.7]. Experimental procedure: Normal tissue was microdissected from unstained sections of paraffin-embedded tissue. DNA was extracted (Qiagen). Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight (Sequenom) for all SNPs. Each SNP was dichotomized a priori into: (1) major homozygote vs (2) minor (heterozygote plus minor homozygote) allele groups. Data analysis was performed centrally, with lab investigators blinded to clinical data. Exact logistic regression was used to derive ORs for non-pCR, using the major homozygote as the reference (2-sided p values). Results: Germline DNA was available in 68 pts; 60 were eligible and began therapy ( Table ). Conclusions: In this homogenous, well-defined cohort, the XRCC1 Arg399Gln minor allele group was associated with lower pCR (p=0.06). Lab data on a panel of additional SNPs have been collected and are under analysis for presentation at the meeting. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- H. H. Yoon
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - M. Powell
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - K. Murphy
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - E. A. Montgomery
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - M. J. Hafez
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - G. Liu
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - A. A. Forastiere
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - A. B. Benson
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - L. R. Kleinberg
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | - M. K. Gibson
- Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Johns Hopkins University, Baltimore, MD; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern University, Chicago, IL; University of Pittsburgh, Pittsburgh, PA
| | | |
Collapse
|
14
|
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009; 20:1242-8. [PMID: 19429872 DOI: 10.1093/annonc/mdn787] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m2 and irinotecan 50 mg/m2 given on days 1 and 8 of a 21-day schedule. MATERIALS AND METHODS Patients who had unresectable/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, measurable disease, Eastern Cooperative Oncology Group performance status of zero to two, and normal bilirubin were eligible. Tumor assessment was carried out every three cycles. RESULTS We enrolled 29 chemotherapy-naive (CN) and 15 chemotherapy-exposed (CE) eligible patients. Principal toxic effects were diarrhea, neutropenia, and hyperglycemia. There were no toxic deaths. There was one early death, from myocardial infarction. Among 26 CN and assessable patients, there were seven (26.9%) with a partial response (PR) and one (3.8%) with a complete response (CR). There were two PRs and one CR among the patients with CE disease. Median time to progression for CN patients was 4.0 months and for CE patients 3.5 months. Median survival for CN eligible patients was 9.0 months and for CE patients 11.4 months. CONCLUSIONS Docetaxel-irinotecan combination given on a weekly x 2 of 3 schedule is promising in the treatment of advanced esophageal cancer.
Collapse
Affiliation(s)
- B Burtness
- Division of Medical Sciences, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Forastiere AA, Trotti AM. Searching for Less Toxic Larynx Preservation: A Need for Common Definitions and Metrics. J Natl Cancer Inst 2009; 101:129-31. [DOI: 10.1093/jnci/djn490] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Kleinberg L, Powell ME, Forastiere AA, Keller S, Anne P, Benson AB. Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4532] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Murphy BA, Dietrich MS, Cmelak AJ, Burtness BA, Forastiere AA. E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Langer CJ, Lee JW, Patel UA, Shin DM, Argiris AE, Quon H, Ridge JA, Forastiere AA. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6006] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19:977-83. [PMID: 18296423 DOI: 10.1093/annonc/mdm591] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Ixabepilone is a tubulin-polymerizing agent with potential activity in squamous cell carcinoma of the head and neck (SCCHN). Patients were eligible who had incurable, measurable SCCHN and less than two prior regimens for metastatic/recurrent disease. Eastern Cooperative Oncology Group performance status of less than or equal to one and adequate renal/hepatic/hematological function were required. Patients were randomly assigned to receive ixabepilone 6 mg/m(2)/day x 5 days every 21 days (arm A) or 20 mg/m(2) on days 1, 8, and 15 of a 28-day cycle (arm B). Each arm accrued taxane-naive and -exposed strata in a two-stage design. The primary end point was response. Eighty-five eligible patients entered; there was one response in a taxane-exposed patient among 32 patients on arm A. Five of 35 taxane-naive patients on arm B had partial responses (14%). No taxane-exposed patient on arm B responded. Common grades 3 and 4 toxic effects were fatigue, neutropenia, and sensory/motor neuropathy. Median survival for arm A taxane-naive and taxane-exposed patients is 5.6 and 6.5 months; for arm B, taxane-naive and taxane-exposed patients is 7.8 and 6.5 months. Weekly ixabepilone 20 mg/m(2) is active in taxane-naive patients with SCCHN. A high incidence of motor and sensory grade 3 neuropathy resulted at this dose and schedule. Further development of ixabepilone in previously treated head and neck cancer is not warranted on the basis of these data.
Collapse
Affiliation(s)
- B A Burtness
- Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
| | | | | | | | | | | |
Collapse
|
20
|
Cohen EE, Vokes EE, Rosen LS, Kies MS, Forastiere AA, Worden FP, Kane MA, Liau KF, Shalinsky DR, Cohen RB. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6008 Background: Elevated VEGF-A and VEGF-C have been reported in thyroid tumor tissue compared with normal thyroid. AG is a potent, small molecule inhibitor of VEGF receptors 1, 2 and 3. The efficacy and safety of AG therapy in pts with advanced thyroid cancers was examined in this single-arm, multi-center study. Methods: 60 pts with metastatic or unresectable locally-advanced thyroid cancer refractory to, or not suitable candidates for, 131iodine (131I) treatment, with measurable disease received AG at a starting dose of 5 mg orally BID. The primary endpoint was response rate (RR) by RECIST criteria. A Simon 2-stage minimax design was used (a=0.1; β=0.1; null RR=5%; alternative RR=20%). Samples were collected pretreatment and q8wks to explore relationships between clinical response and plasma soluble proteins. Results: Median age was 59 yrs (26–84), 35 (58%) were male. Histological subtypes included papillary: 29 pts (48%); follicular: 15 pts (25%)-11 (18%) with Hurthle cell variant; medullary: 12 pts (20%); anaplastic: 2 pts (3%), and other/unknown: 2 pts (3%). 53 pts (88%) had prior surgery, 42 (70%) had prior 131I treatment, 27 (45%) had prior external beam radiation, and 9 (15%) had prior chemotherapy. Partial response (PR) by investigator report was achieved in 13 pts (22% CI: 12.1, 34.2), with 31- 68% maximum tumor regression and duration of response (DOR) of 1–16 months. 30 pts (50%) have stable disease with a duration range of 4–13 months and 13–67% maximum tumor regression in 28 pts. Response assessments are ongoing. The treatment duration range is 6–670 days with 38 pts currently on study. Median PFS has not been reached with a median follow up of 273 days. The most common treatment-related adverse events were fatigue (37%), proteinuria (27%), stomatitis/mucositis (25%), diarrhea (22%), hypertension (20%) and nausea (18%). AG therapy consistently decreased soluble VEGFR2 and VEGFR3, and increased VEGF in the blood, demonstrating pharmacodynamic activity against targeted VEGF receptors. Conclusions: AG has substantial anti-tumor activity in advanced thyroid cancer with demonstrated pharmacodynamic activity. A global pivotal trial testing AG in doxorubicin refractory thyroid cancer is ongoing. [Table: see text]
Collapse
Affiliation(s)
- E. E. Cohen
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - E. E. Vokes
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - L. S. Rosen
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - M. S. Kies
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - A. A. Forastiere
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - F. P. Worden
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - M. A. Kane
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - K. F. Liau
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - D. R. Shalinsky
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - R. B. Cohen
- University of Chicago, Chicago, IL; Premiere Oncology, California, Santa Monica, CA; MD Anderson Cancer Center, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; University of Michigan, Ann Arbor, MI; University of Colorado, Denver, CO; Pfizer, Inc., San Diego, CA; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
21
|
Ma W, Jimeno A, Kulesza P, Chan A, Zhang X, Messersmith WA, Gillison ML, Pomper MG, Forastiere AA, Hidalgo M. Early prediction of anti-epidermal growth factor receptor (EGFR) therapy with 18[F]FDG-PET: A preclinical and clinical correlation. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14064 Background: Predictive biomarkers for response to anti-EGFR therapy are of significant clinical importance. We hypothesized that early changes in 18[F]FDG tumor uptake predict response to anti-EGFR therapy. We investigated this in a mice model and correlated these findings with human patients undergoing anti-EGFR therapy. Methods: Mice bearing two head and neck squamous cell cancer (HnNSCC) xenografts (Hep2, Cal27) received vehicle or erlotinib for 3 weeks. 18[F]FDG uptake were imaged with small animal micro- PET at baseline and after 1 week of therapy, and reported in SUVmax. For clinical correlation, human patients with HnNSCC receiving erlotinib were identified from an ongoing clinical trial. 18[F]FDG-PET images were obtained at baseline and after 2 weeks of erlotinib monotherapy. Tumor specimens were obtained by fine-needle aspiration biopsy at the same time as PET. A panel of pharmacodynamic markers (including Ki-67 and pMAPK) were assessed . Results: Hep2 was resistant to erlotinib therapy (Tumor/Control [T/C]: 0.8) while Cal27 was sensitive (T/C: 0.2). SUVmax in the resistant Hep2 xenografts was not significantly different from the control (86% ± 70% of control) while SUVmax in the treated sensitive Cal27 xenografts showed a significant decrease than control (-2% ± 7%). Ki-67 in the treated Hep2 was not significantly different from control while that in Cal27 was <50% of control. For clinical correlation, ki-67 score was higher after 2 weeks in the patient resistant to erlotinib monotherapy by 18[F]FDG-PET (SUVmax increased by 14%, ± 11%) and was lower in the patient who was 18[F]FDG-PET sensitive (SUVmax decreased by 56%, ± 13%). pMAPK decreased in all cases and had a poor correlation with efficacy. Conclusions: Early dynamic changes in 18[F]FDG tumor uptake is predictive of response to anti-EGFR therapy and correlates with changes in ki-67 expression, both in a preclinical and a clinical scenario. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. Ma
- Johns Hopkins University, Baltimore, MD
| | - A. Jimeno
- Johns Hopkins University, Baltimore, MD
| | | | - A. Chan
- Johns Hopkins University, Baltimore, MD
| | - X. Zhang
- Johns Hopkins University, Baltimore, MD
| | | | | | | | | | | |
Collapse
|
22
|
Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, Trotti A, Ridge J, Ensley J, Chao C, Cooper J. Long-term results of Intergroup RTOG 91–11: A phase III trial to preserve the larynx—Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5517] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5517 Background: The 2-year results of Intergroup RTOG 91–11 were published in 2003 (NEJM 349:2091–8,2003). We now present the 5-year results (after median follow-up for surviving patients of 6.9 years) of 515 eligible pts with resectable stage III or IV (excluding T1 and high volume T4), cancer of the glottic or supraglottic larynx. Methods: Patients were randomized to induction cisplatin/5-FU (CF) with responders then receiving RT (I+RT) (n = 173); or concurrent cisplatin (100 mg/m2 q 21 days × 3) and RT (CRT) (n = 171); or RT alone (R) (n = 171). Laryngectomy was performed for < partial response to induction CF, for persistent/recurrent disease or for laryngeal dysfunction. Results: At 5 years, laryngectomy-free survival (LFS) was significantly better with either I+RT (44.6%, p = 0.011) or CRT (46.6%, p = 0.011) compared to R (33.9%). There was no difference in LFS between I+RT and CRT (p = 0.98). Laryngeal preservation (LP) was significantly better with CRT (83.6%) compared to I+RT (70.5%, p = 0.0029) or R (65.7%, p = 0.00017). Local-regional control (LRC) was significantly better with CRT (68.8%) compared to I+RT (54.9%, p = 0.0018) or R (51%, p = 0.0005). I+RT compared to R for LP and LRC showed no significant difference (p = 0.37 and 0.62, respectively). The distant metastatic rate was low (I+RT 14.3%, CRT 13.2%, R 22.3%) with a trend (p ∼0.06) for benefit from chemotherapy. Disease-free survival (DFS) was significantly better with either I+RT (38.6%, p = 0.016) or CRT (39%, p = 0.0058) compared to R (27.3%). Overall survival rates were similar for the first 5 years (I+RT 59.2%, CRT 54.6%, R 53.5%); thereafter I+RT had a non-significant lower death rate. Compared to CRT, significantly more pts in the R group died of their cancer (34% vs 58.3%, p = 0.0007); the rate for I+RT was 43.8%. Conclusion: These 5-year results differ from the 2-year analysis by a significant improvement in LFS now seen for both I+RT and CRT treatments compared to R. For the endpoints of LP and LRC, CRT is still the superior treatment with no advantage seen to the addition of induction CF to R. There is no significant difference in overall survival. [Table: see text]
Collapse
Affiliation(s)
- A. A. Forastiere
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - M. Maor
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - R. S. Weber
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - T. Pajak
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - B. Glisson
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - A. Trotti
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - J. Ridge
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - J. Ensley
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - C. Chao
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| | - J. Cooper
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer Institute, Detroit, MI; Maimonides Cancer Center, New York, NY
| |
Collapse
|
23
|
Burtness B, Goldwasser MA, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5532] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5532 Background: Ixabepilone is a novel tubulin-polymerizing agent, with potential activity in SCCHN. Methods: Patients (pts) were eligible who had incurable, measurable SCCHN. ≤ 2 prior regimens for metastatic/recurrent disease were permitted, including taxanes. ECOG PS 0 or 1, ANC ≥ 1500/ml and adequate renal/hepatic function were required. Pts were randomized to ixabepilone 6 mg/m2/d 60 minute (min) infusion x 5 days (d) q 21 d [Arm A], or 20 mg/m2 60 min infusion d1, 8, and 15 q 28 d [Arm B], with diphenhydramine premedication. Tumor assessment was q 6 weeks. Each arm accrued taxane-naive (Tax-N) and -exposed (Tax-E) patients as separate strata, in a 2-stage design. The primary endpoint was response.16 pts entered each group in the first stage. If 1 response was observed in any group, it continued to 32 pts. Results: 85 eligible pts entered. Male 69, ECOG PS (1) 58, metastatic disease 66. 15 Tax-E and 17 Tax-N eligible pts entered stage 1 of Arm A. There were no responses with this dose and schedule. 35 eligible Tax-N pts were accrued to Arm B and 5 had partial responses (14.3%, 90% CI 5.9%,28.2%), 11 stable and 9 progressive disease. 10 in this group were inevaluable (5 died before restaging, 2 were never treated).18 eligible Tax-E pts entered Arm B and none responded. On Arm A, 2/16 Tax-N pts developed grade (gd) 3/4 anemia (13%), and 4/16 (25%) developed gd 3 fatigue. Other gd 3/4 toxicities occurred in < 8% of pts on Arm A. On Arm B, 9/33 (27%) Tax-N pts experienced gd 3/4 leukopenia, 3/33 (9%) gd 3/4 anemia 7 gd 3/4 fatigue (21%), 4 gd 3 nausea (12%), 9 (27%) gd 3 sensory and 2 (6%) gd 3 motor neuropathy. 2/21 Tax-E pts on Arm B experienced gd 4 neutropenia (10%), 6 gd 3 fatigue (29%), 3 gd 3 motor (14%) and 2 gd 3 sensory neuropathy (10%). Median follow up for eligible pts is 31.5 months (mo). 75 have died. Median survival for Arm A Tax-N is 5.62 mo (CI 4.0, 10.0); for Arm A Tax-E is 6.5 mo (CI 2.7, 8.8); for Arm B Tax-N is 7.8 mo (CI 3.3, 8.9) and for Arm B Tax-E is 6.5 mo (CI 2.0, 11.3). Conclusions: Ixabepilone 20 mg/m2 d1,8,15 q 28 d is active and tolerable in taxane-naive pts with metastatic/recurrent SCCHN. A high incidence of motor and sensory gd 3 neuropathy results at this dose and schedule in patients with previous taxane exposure. [Table: see text]
Collapse
Affiliation(s)
- B. Burtness
- Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Thomas Jefferson University, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD
| | - M. A. Goldwasser
- Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Thomas Jefferson University, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD
| | - R. Axelrod
- Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Thomas Jefferson University, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD
| | - A. Argiris
- Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Thomas Jefferson University, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD
| | - A. A. Forastiere
- Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Thomas Jefferson University, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
24
|
Cmelak AJ, Li S, Murphy B, Burkey B, Adams GL, Cannon M, Pinto H, Rosenthal DI, Ridge JA, Forastiere AA. Locally advanced resectable larynx (L) or oropharynx (OP) cancer: Updated results of organ preservation trial ECOG 2399. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5527] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5527 Background: Taxane-based concurrent chemoradiation (CCR) for head and neck cancers has proven feasible and has a favorable toxicity profile compared to concurrent cisplatin and radiation. This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable Stage III/IV L and OP patients. Methods: Eligibility: Resectable stage T2N+, or T3-T4N0–3M0 biopsy-proven squamous Ca, age ≥18, PS 0–2, good organ function, and no prior chemotherapy or radiation. Treatment: induction paclitaxel (P) 175 mg/m2 and carboplatin (C) AUC 6 for 2 cycles q21d followed by concurrent P 30 mg/m2 q7d with 70 Gy if no evidence of progression. Weekly epoetin alpha 40kU was used if Hgb ≤15 (male) or ≤14 (female). The primary endpoint is organ preservation (freedom from salvage surgery with preserved speech and swallowing). Results: 105/111 pts (69 OP, 36 larynx) were eligible. Median FU is 33 months. No grade 5 toxicities occurred. 94% received full dose RT and 91% received ≥5 cycles of concurrent paclitaxel. At one year post-treatment, 13 (12%) patients required salvage surgery at the primary site (7-L, 6-OP), and 6 pts (6%) progressed and died (3-L, 3-OP). 1 pt (1%) died without progression and 85 pts (81%) are alive without progression (25-L, 60-OP). 12 pts (10%) have developed distant mets (6-L, 6-OP). 1-yr and 2-yr PFS for all pts is 77% and 64%. 12/69 OP and 9/36 L pts have died of disease. 1-yr event-free survival (EFS = no salvage surgery, recurrence or death) is 72% (77%-OP, 64%-L), and 2-yr EFS is 57% (68%-OP, 34%-L) (p = 0.02). 1-yr OS is 93%, 2-yr OS is 74% (OP vs. L p = 0.11). Conclusions: This regimen is well tolerated and is feasible in a multi-institutional setting. EFS with this regimen is lower than expected in larynx patients. The benefit of induction chemotherapy in this setting remains unproven but does not preclude CCR delivery. Funded, in part, by Bristol-Myers Squibb. [Table: see text]
Collapse
Affiliation(s)
- A. J. Cmelak
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - S. Li
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - B. Murphy
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - B. Burkey
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - G. L. Adams
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - M. Cannon
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - H. Pinto
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - D. I. Rosenthal
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - J. A. Ridge
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| | - A. A. Forastiere
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Cancer Center of Kansas, Wichita, KS; Stanford University, Palo Alto, CA; M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
25
|
Gillison ML, Glisson BS, O’Leary E, Murphy BA, Levine MA, Kies MS, Chan D, Forastiere AA. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5511] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5511 Background: EGFR expression is associated with poor prognosis and resistance of HNSCC to therapy. EGFR/Her2/neu heterodimers may potentiate receptor signaling and therapy resistance. T enhances cytotoxic effects of C and P in Her2/neu+ cell lines. Methods: A phase II trial evaluated the response rate (RR) of HNSCC pts to TPC as a function of Her2/neu and EGFR expression by immunohistochemistry (IHC). Secondary outcomes included toxicity, one-year progression-free (PFS) and overall (OS) survival. Eligible pts had M or R HNSCC, ECOG PS 0–1, CrCl >50 ml/min, and ANC >1500. Chemotherapy regimen consisted of P (175 mg/m2) and C (75 mg/m2) IV on day 1 and T (4 mg/kg day 1, cycle 1, 2 mg/kg subsequent) IV on day 1, 8 and 15 of 21. Paraffin embedded tumor was analyzed for Her2/neu (HercepTest) and EGFR (Zymed Lab) expression by IHC and for Her2/neu amplification by FISH (−/+) at LabCorp. Two-stage Simon design had 80% power for a 15% improvement in RR over 35% and required response in ≥ 14/42 pts by ECOG response criteria. Results: 61 pts (55 R HNSCC) received a median of 4 cycles (range 1–14) of TPC. Membrane staining of ≥ 10% of cells was observed for Her2/neu in 4/58 (6.9%, 95% CI 2–17) and for EGFR in 41/57 (72%, 95% CI 58–83). Her2/neu amplification was absent in 55/55 (0%, one-sided 97.5% CI 0–6.7) tumors. A RR of 36% (95% CI 24–50) was observed in 58 evaluable pts. RR was lower in pts with ≥ 10% staining by EGFR (25% versus 62.5%, p = 0.01). Her2/neu expression had no effect on RR (p = 0.75). Toxicities included two grade 5 dehydration/hypokalemia, and grade 3–4 neutropenia, fatigue, infection, nausea, vomiting, and neuropathy were common. Median follow-up was 4.2 yrs. For all 61 pts: median TTP was 4.3 mos, PFS 19.8% (95% CI 10.6–30.9) and OS 44% (95% CI 31.6–56.2) at 1 yr. Pts with <10% EGFR membrane staining had improved median PFS (6.7 vs 3.1 mos, p = 0.003) and OS (16.1 vs 7.4 mos, p = 0.005) when compared to patients with tumors with ≥ 10% EGFR. Conclusions: T did not improve RR to PC, likely because Her2/neu gene amplification and expression was rare. Tumor EGFR status significantly affected RR, PFS, and OS to the underlying regimen of PC. Sponsored by Bristol-Myers Squibb, Genentech, and Damon Runyon Cancer Research Foundation (MG). [Table: see text]
Collapse
Affiliation(s)
- M. L. Gillison
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - B. S. Glisson
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - E. O’Leary
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - B. A. Murphy
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - M. A. Levine
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - M. S. Kies
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - D. Chan
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| | - A. A. Forastiere
- Johns Hopkins University, Baltimore, MD; M. D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Cancer Center at Greater Baltimore Medical Center, Baltimore, MD
| |
Collapse
|
26
|
Gibson MK, Brock M, Montgomery E, Herman J, Baylin S, Heath E, Heitmiller R, Forastiere AA. Pathologic downstaging with taxane-based neoadjuvant chemotherapy correlates with increased survival in patients with locally advanced esophageal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. K. Gibson
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - M. Brock
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - E. Montgomery
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - J. Herman
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - S. Baylin
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - E. Heath
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - R. Heitmiller
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| | - A. A. Forastiere
- The Sidney Kimmel Comprehensive Cancer Ctr at J, Baltimore, MD; The Johns Hopkins Hosp, Baltimore, MD; Karmanos Cancer Institute, Detroit, MI; The Union Memorial Hosp, Baltimore, MD
| |
Collapse
|
27
|
Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004; 22:2856-64. [PMID: 15254053 DOI: 10.1200/jco.2004.12.012] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck. PATIENTS AND METHODS The Radiation Therapy Oncology Group developed this three-arm randomized phase II trial. Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible. Each of three arms proposed a radiation schedule of 70 Gy in 35 fractions. Patients on arm 1 were to receive cisplatin 10 mg/m(2) daily and fluorouracil (FU) 400 mg/m(2) continuous infusion (CI) daily for the final 10 days of treatment. Treatment on arm 2 consisted of hydroxyurea 1 g every 12 hours and FU 800 mg/m(2)/d CI delivered with each fraction of radiation. Arm 3 patients were to receive weekly paclitaxel 30 mg/m(2) and cisplatin 20 mg/m(2). Patients randomly assigned to arms 1 and 3 were to receive their treatments every week; patients on arm 2 were to receive their therapy every other week. RESULTS Between 1997 and 1999, 241 patients were entered onto study; 231 were analyzable. Ninety-two percent, 79%, and 83% of patients on arms 1, 2, and 3, respectively, were able to complete their radiation as planned or with an acceptable variation. Fewer than 10% of patients had unacceptable deviations or incomplete chemotherapy in the three arms. Estimated 2-year disease-free and overall survival rates were 38.2% and 57.4% for arm 1, 48.6% and 69.4% for arm 2, and 51.3% and 66.6% for arm 3. CONCLUSION We have demonstrated that three different approaches of concurrent multiagent chemotherapy and radiation were feasible and could be delivered to patients in a multi-institutional setting with high compliance rates.
Collapse
Affiliation(s)
- A S Garden
- Department of Radiation Oncology, Unit 97, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere AA. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Gibson
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Yale Cancer Center, New Haven, CT; Union Memorial Hospital, Baltimore, MD
| | - B. Burtness
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Yale Cancer Center, New Haven, CT; Union Memorial Hospital, Baltimore, MD
| | - E. Heath
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Yale Cancer Center, New Haven, CT; Union Memorial Hospital, Baltimore, MD
| | - R. Heitmiller
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Yale Cancer Center, New Haven, CT; Union Memorial Hospital, Baltimore, MD
| | - A. A. Forastiere
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Yale Cancer Center, New Haven, CT; Union Memorial Hospital, Baltimore, MD
| |
Collapse
|
29
|
Abstract
Barrett's esophagus is a premalignant condition in which normal squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium. It is a known risk factor for the development of esophageal adenocarcinoma. With the incidence of esophageal adenocarcinoma rising, it is reasonable to study Barrett's esophagus as a potential target for therapy that may prevent, delay and/or reverse ongoing tumorigenic processes. Epidemiologic and animal studies support the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the chemoprevention of several cancers, including esophageal cancer. Cyclo-oxygenase-2 (COX-2) inhibitors are a new class of NSAIDs that inhibit prostaglandin synthesis by selectively blocking the COX-2 enzyme. The COX-2 enzyme has been reported to be over-expressed in premalignant and malignant states, including in Barrett's esophagus and esophageal adenocarcinoma. The Chemoprevention for Barrett's Esophagus Trial (CBET) is a phase IIb, multicenter, randomized, double-masked, placebo-controlled study of the selective COX-2 inhibitor, celecoxib, in patients with Barrett's dysplasia. The sample size is 200 patients with high or low grade Barrett's dysplasia. Celecoxib is administered orally, 200 mg twice per day; the dosing schedule for placebo is the same. Randomization is stratified by dysplasia grade and by clinic. Endoscopy with biopsies is performed at specified time intervals according to the highest grade of dysplasia determined at randomization. The primary outcome measure is the change from baseline to 1 year in the proportion of biopsies exhibiting dysplasia. Secondary outcomes include change from baseline in the maximal grade, extent and surface area of dysplasia. Tertiary outcomes will include measurements of various relevant biomarkers.
Collapse
Affiliation(s)
- E I Heath
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, Wu TT. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 2001; 7:2765-9. [PMID: 11555590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE E-cadherin, a M(r) 120,000 transmembrane glycoprotein, mediates calcium-dependent intercellular adhesion that is essential for normal tissue homeostasis. Loss of E-cadherin occurs in a variety of epithelial tumors and is correlated with invasion and metastasis. In esophageal adenocarcinoma, reduction of E-cadherin expression has been demonstrated previously, but mutations of the gene (CDH1) are rare. EXPERIMENTAL DESIGN In this study, we used a nested PCR approach to examine the methylation status of the 5' CpG island of E-cadherin in esophageal specimens obtained from individuals with and without a history of esophageal cancer. RESULTS In four individuals without esophageal cancer, E-cadherin was completely unmethylated in normal squamous cell-lined esophageal mucosa. In contrast, in patients with esophageal adenocarcinoma, E-cadherin was methylated in 26 of 31 (84%) tumor specimens. In the majority of cases, matched normal tissue (esophagus or stomach) from each patient was completely unmethylated. By immunostaining, methylated tumor samples demonstrated heterogeneously decreased membranous E-cadherin staining. CONCLUSIONS These data suggest that epigenetic silencing via aberrant methylation of the E-cadherin promoter is a common cause of inactivation of this gene in esophageal adenocarcinoma.
Collapse
Affiliation(s)
- P G Corn
- University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.
| | | | | | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- E I Heath
- Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
| | | |
Collapse
|
32
|
Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19:1088-95. [PMID: 11181673 DOI: 10.1200/jco.2001.19.4.1088] [Citation(s) in RCA: 122] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine dose-response effects and the activity of paclitaxel combined with cisplatin in patients with incurable squamous cell carcinoma of the head and neck. PATIENTS AND METHODS Two hundred ten patients with locally advanced, recurrent, or metastatic disease were randomly placed in either Arm A, paclitaxel 200 mg/m(2) (24-hour infusion) + cisplatin 75mg/m(2) + granulocyte colony-stimulating factor, or Arm B, paclitaxel 135 mg/m(2) (24-hour infusion) + cisplatin 75 mg/m(2). Cycles were repeated every 3 weeks until progression or a total of 12 cycles for complete responses. Primary outcomes were event-free and overall survival. RESULTS No significant differences in outcomes were observed between the high- and low-dose paclitaxel regimens. The estimated median survival was 7.3 months (95% confidence interval, 6.0 to 8.6). The 1-year survival rate was 29%, and event-free survival was 4.0 months. The objective response rate (complete response plus partial response) was 35% for the high-dose patients and 36% for the low-dose patients. Myelosuppression was the most frequent toxicity: grade 3 or 4 granulocytopenia, 70% of patients in Arm A and 78% in Arm B; febrile neutropenia, 27% of patients in Arm A and 39% in Arm B. Grade 5 toxicities occurred in 22 patients (10.5%). Treatment was terminated early in 31% because of excessive toxicity or patient refusal. CONCLUSION This phase III multicenter trial showed (1) no advantage for high-dose paclitaxel and (2) excessive hematologic toxicity associated with both regimens. Therefore, neither of the paclitaxel regimens evaluated in this trial can be recommended.
Collapse
|
33
|
Choi YW, Heath EI, Heitmiller R, Forastiere AA, Wu TT. Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000; 13:1055-9. [PMID: 11048797 DOI: 10.1038/modpathol.3880194] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Beta-catenin plays important roles in both intercellular adhesion and signal transduction. Mutations in the beta-catenin or adenomatous polyposis coli (APC) gene can alter the degradation of beta-catenin and cause aberrant accumulation of beta-catenin result in increased transcription of target genes. The dysregulated APC/beta-catenin pathway has been recently discovered as an important mechanism of tumorigenesis in various cancers, but its role in esophageal adenocarcinomas is not clear. Therefore, we studied the beta-catenin gene mutation, allelic loss of chromosome 5q, and APC gene mutation in esophageal and esophagogastric junction adenocarcinomas. Two (2%) somatic mutations in exon 3 of the beta-catenin gene, encompassing the region for glycogen synthase kinase-3beta phosphorylation, were detected from 109 adenocarcinomas. Chromosomal allelic loss on 5q was frequent in 45.3% (44/97) of tumors. Only one missense mutation in the mutation cluster region of the APC gene was detected from 38 esophageal and esophagogastric junction adenocarcinomas with the 5q allelic loss. Our results based on partial screening mutational analyses indicate that mutations of APC/beta-catenin pathway, unlike in colorectal carcinoma, involve only a small subset of esophageal and esophagogastric junction adenocarcinoma.
Collapse
Affiliation(s)
- Y W Choi
- Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA
| | | | | | | | | |
Collapse
|
34
|
Forastiere AA. Head and neck cancer: overview of recent developments and future directions. Semin Oncol 2000; 27:1-4. [PMID: 10952432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- A A Forastiere
- Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
| |
Collapse
|
35
|
Heath EI, Kaufman HS, Talamini MA, Wu TT, Wheeler J, Heitmiller RF, Kleinberg L, Yang SC, Olukayode K, Forastiere AA. The role of laparoscopy in preoperative staging of esophageal cancer. Surg Endosc 2000; 14:495-9. [PMID: 10858480 DOI: 10.1007/s004640001024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Diagnostic laparoscopy has been used to determine resectability and to prevent unnecessary laparotomy in patients with advanced esophageal cancer. The objective of this prospective study was to evaluate the role of laparoscopy in conjunction with computed tomography (CT) scan in staging patients with esophageal cancer. METHODS From March 1995 to October 1998, 59 patients with biopsy-proven esophageal cancer underwent diagnostic laparoscopy with concurrent vascular access device and feeding jejunostomy tube placement. RESULTS Laparoscopy changed the treatment plan in 10 of 59 patients (17%). Of the patients with normal-appearing regional or celiac nodes, 78% were confirmed by biopsy to be tumor free, whereas 76% of patients with abnormal-appearing nodes were confirmed by biopsy to have node-positive disease. CONCLUSIONS Diagnostic laparoscopy is useful for detecting and confirming nodal involvement and distant metastatic disease that potentially would alter treatment and prognosis in patients with esophageal cancer.
Collapse
Affiliation(s)
- E I Heath
- Department of Medical Oncology, Johns Hopkins Oncology Center, 1650 Orleans Street, G89, Baltimore, MD 21231, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Heath EI, Limburg PJ, Hawk ET, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park) 2000; 14:507-14; discussion 518-20, 522-3. [PMID: 10826312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Esophageal cancer, with an estimated number of 12,300 new cases in the year 2000, is relatively uncommon in the United States but produces a high number of annual deaths, estimated at 12,100. Moreover, the incidence of the adenocarcinoma histologic type of esophageal cancer has been rising over the past two decades. Identification of risk factors could lead to primary prevention, as well as earlier diagnosis, treatment, and increased survival. Multiple risk factors are associated with the development of esophageal adenocarcinoma. These include Barrett's esophagus, acid peptic disorders, motor disorders of the esophagus, other malignancies, medications, environmental exposures, diet, and nutrition. However, no one particular risk factor is responsible for the rising incidence of esophageal cancer. Several preventive strategies are under investigation using such agents as nonsteroidal anti-inflammatory drugs (NSAIDs), selenium, alpha-difluoromethylornithine (DFMO), and retinoids. As we gain more insight into the biology of this disease, other risk factors will hopefully be identified that will enable us to develop effective prevention strategies and, thus, reverse the current rising incidence of esophageal carcinoma.
Collapse
Affiliation(s)
- E I Heath
- Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
| | | | | | | |
Collapse
|
37
|
Abstract
Neoadjuvant chemoradiation (NAC) therapy protocols were developed to improve survival in patients with resectable esophageal cancer. Our experience with two consecutive NAC therapy trials is reviewed. Both studies included patients with localized squamous cell cancer and adenocarcinoma. Patients were treated with cisplatinum 26 mg/m2/day (days 1-5 and 26-30), 5-Fluorouracil (5-FU) 300 mg/m2/day (days 1-30), concurrent radiotherapy (4400 cGy) followed by esophagectomy. In the second trial, adjuvant taxol was added. The first protocol had 50 patients. Two patients died, both before surgery, one from sepsis. There was no residual viable tumor (CR) in 19 (40%) patients. The median survival time was 31 months. The 5-year survival rate of 36% compared favorably with concurrent 5-year survival of 18% for surgery alone. Forty-one patients were enrolled in the second trial. All underwent surgery. There were no treatment or operative deaths. Survival data for this group is maturing. Combined results from both protocols are: treatment mortality of 2.2%, complete response rate of 37%, and a median and 3-year disease-specific survival of 42 months and 54%, respectively. We conclude that NAC followed by surgery improves survival over surgery alone and that CR is predictive of improved survival.
Collapse
Affiliation(s)
- R F Heitmiller
- Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
| | | | | | | |
Collapse
|
38
|
Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000; 18:868-76. [PMID: 10673530 DOI: 10.1200/jco.2000.18.4.868] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This phase II trial evaluated continuous-infusion cisplatin and fluorouracil (5-FU) with radiotherapy followed by esophagectomy. The objectives of this trial were to determine the complete pathologic response rate, survival rate, toxicity, pattern of failure, and feasibility of administering adjuvant chemotherapy in patients with resectable cancer of the esophagus treated with preoperative chemoradiation. PATIENTS AND METHODS Patients were staged using computed tomography, endoscopic ultrasound, and laparoscopy. The preoperative treatment plan consisted of continuous intravenous infusion of cisplatin and 5-FU and a total dose of 44 Gy of radiation. Esophagogastrectomy was planned for approximately 4 weeks after the completion of chemoradiotherapy. Paclitaxel and cisplatin were administered as postoperative adjuvant therapy. RESULTS Forty-two patients were enrolled onto the trial. Of the 39 patients who proceeded to surgery, 29 responded to preoperative treatment: 11 achieved pathologic complete response (CR) and 18 achieved a lower posttreatment stage. Five patients had no change in stage, whereas eight had progressive disease (four with distant metastases and four with increases in the T and N stages). At a median follow-up of 30.2 months, the median survival time has not been reached and the 2-year survival rate is 62%. The median survival of pathologic complete responders has not been reached, whereas the 2-year survival rate of this group is 91% compared with 51% in patients with complete tumor resection with residual tumor (P =.03). CONCLUSION An excellent survival rate, comparable to that of our prior preoperative trial, was achieved with lower doses of preoperative cisplatin and 5-FU concurrent with radiotherapy.
Collapse
Affiliation(s)
- E I Heath
- Departments of Oncology, Surgery, Medicine, and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287-8934, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Forastiere AA. Taxoids in head and neck cancer: the American approach. Acta Otorhinolaryngol Belg 2000; 53:253-7. [PMID: 10635404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The taxoids docetaxel and paclitaxel entered into clinical trials in the 1980s. Paclitaxel has dominated clinical investigations in the United States while docetaxel gained a foothold early in Europe. Now both agents are under intensive study in both countries. The Eastern Cooperative Oncology Group (ECOG) conducted a series of paclitaxel trials in patients with recurrent or metastatic squamous cell head and neck. The current study directly compares paclitaxel + cisplatin to cisplatin + 5-FU. Similarly, an international trial is in progress directly comparing docetaxel-based chemotherapy to cisplatin + 5-FU. For patients with locally advanced disease, phase I-II trials evaluating various doses and schedules of paclitaxel or docetaxel administered concurrently with radiotherapy are in progress or recently reported in preliminary form. No one regimen is clearly preferred. The results of selected studies and trials in progress in the United States are reviewed.
Collapse
Affiliation(s)
- A A Forastiere
- Johns Hopkins University, School of Medicine, Department of Oncology, Johns Hopkins Oncology Center, Baltimore, USA
| |
Collapse
|
40
|
Forastiere AA. Induction and adjuvant chemotherapy for head and neck cancer: future perspectives. Acta Otorhinolaryngol Belg 2000; 53:277-80. [PMID: 10635408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Induction and adjuvant chemotherapy have been studied in combined modality trials over the last two decades. Induction chemotherapy as a strategy has failed to improve survival or local-regional control although some studies have reported a decrease in the rate of development of distant metastases. The role of induction chemotherapy is limited to preserving the larynx for patients with larynx or hypopharynx primaries. Trials of adjuvant chemotherapy or chemoradiation in resected patients suggest benefit for those with high risk features (multiple involved nodes, extracapsular extension, positive surgical margin). Definitive randomized studies are in progress in the United States and Europe. New targeted therapies will be investigated in future trials to improve survival.
Collapse
Affiliation(s)
- A A Forastiere
- Johns Hopkins University, School of Medicine, Department of Oncology, Johns Hopkins Oncology Center, Baltimore, USA
| |
Collapse
|
41
|
Forastiere AA, Trotti A. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999; 91:2065-6. [PMID: 10601369 DOI: 10.1093/jnci/91.24.2065] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5:4097-104. [PMID: 10632346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Neoadjuvant cisplatin-based chemotherapy has been widely used in the last decade for organ preservation or unresectable disease in advanced stage head and neck cancer. We examined the expression of a series of tumor markers that have been associated with chemotherapy resistance in pretreatment biopsies from 68 patients who received cisplatin-based neoadjuvant chemotherapy at either of two institutions. Patients received either cisplatin/5-fluorouracil (n = 49) or cisplatin/paclitaxel (n = 19). Expression of p53, glutathione S-transferase pi (GSTpi), thymidylate synthase (TS), c-erbB2, and multidrug resistance-associated protein was examined by immunohistochemistry. Expression of glutathione synthetase mRNA was measured by in situ hybridization. The overall response rate for cisplatin-based neoadjuvant treatment was 79%. The expression of several of the tumor markers was associated with resistance to neoadjuvant treatment, but none reached statistical significance. Overall survival (OS) was strongly correlated with the absence of p53 expression. The OS at 3 years was 81% in the p53-negative group, whereas it was 30% in the p53-positive group for patients treated with neoadjuvant chemotherapy (P < 0.0001). Expression of GST pi and TS was also significantly correlated with decreased OS after neoadjuvant treatment. At 3 years, the OS rate was 82% in the low GSTpi score group, compared to 46% in the high GSTpi score group (P = 0.0018). In the TS-negative group, the 3-year OS rate was 71% compared with 40% in the TS-positive group (P = 0.0071). We conclude that p53, GSTpi, and TS may be clinically important predictors of survival in patients receiving neoadjuvant chemotherapy for head and neck cancer.
Collapse
Affiliation(s)
- H Shiga
- Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Heath EI, Holbrook JT, Forastiere AA. Gastroesophageal reflux and adenocarcinoma of the esophagus. N Engl J Med 1999; 341:536-7; author reply 537-8. [PMID: 10447438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
44
|
Gillison ML, Forastiere AA. Larynx preservation in head and neck cancers. A discussion of the National Comprehensive Cancer Network Practice Guidelines. Hematol Oncol Clin North Am 1999; 13:699-718, vi. [PMID: 10494508 DOI: 10.1016/s0889-8588(05)70087-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The management of advanced cancers of the larynx and hypopharynx has become increasingly complex as different treatment modalities, including surgery, radiation, and chemotherapy, have been combined with the goal of improving local disease control and disease-specific survival. A union of 17 comprehensive cancer centers in the United States, the National Comprehensive Care Network (NCCN), was formed in 1995 to promote state-of-the-art cancer care. To achieve this goal, multidisciplinary panels of experts from member institutions have created disease-specific practice guidelines for the evaluation and treatment of cancer patients, including those with head and neck cancers. Although detailed analysis of surgical methods and radiation techniques are beyond the scope of this article, the evolving laryngeal preservation strategies for patients with advanced, resectable hypopharyngeal or laryngeal (including supraglottic and glottic) cancers are reviewed using relevant sections of the NCCN practice guidelines as a framework for discussion.
Collapse
Affiliation(s)
- M L Gillison
- Department of Medical Oncology, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
| | | |
Collapse
|
45
|
Affiliation(s)
- W A Flood
- Hershey Medical Center, PA 17033, USA
| | | |
Collapse
|
46
|
Flood W, Lee DJ, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere AA. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Radiat Oncol 1999; 9:64-9. [PMID: 10210542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Chemotherapy has been integrated into the initial treatment of patients with locally advanced squamous cell cancer of the head and neck to improve locoregional control and survival. Two strategies for improving these outcomes are the use of new, potentially more effective drugs either with concurrent radiotherapy or as induction regimens. Because of its inherent activity against squamous cell cancer of the head and neck and its radiation-sensitizing properties, paclitaxel may be a valuable agent in the treatment of this patient population. We describe the preliminary results of two trials that evaluated the combination of paclitaxel and cisplatin in patients with locally advanced disease: a phase I trial of weekly paclitaxel and cisplatin with concurrent postoperative radiation therapy in patients with high-risk disease and a phase I/II trial of paclitaxel as a 96-hour infusion in combination with cisplatin as induction therapy. These studies identified tolerable doses of paclitaxel and cisplatin administered in these settings, with apparent clinical activity. These trials formed the basis for subsequent evaluation of induction paclitaxel and cisplatin followed by definitive radiotherapy and concurrent weekly paclitaxel and cisplatin plus radiotherapy.
Collapse
Affiliation(s)
- W Flood
- Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21234, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Controlled trials testing the concept of laryngeal preservation for patients with locally advanced stage III and IV cancers of the larynx or hypopharynx were initiated in the mid-1980s. Three randomized trials, evaluating the same cisplatin plus 5-fluorouracil induction chemotherapy regimen and conventional radiotherapy compared with surgery and radiotherapy, have been completed, and the results of two are published. In addition, a meta-analysis of these three trials was completed. The studies are critically reviewed. Conclusions from these trials are that the induction approach is feasible; local and regional control are not improved, whereas distant metastases are delayed; there is no evidence of a difference in overall survival; and of the patients alive at 3 and 5 years, a functional larynx can be preserved in 67% and 58%; there are not enough data to know if there are differences in outcome by subsite. Several unanswered questions are being addressed in phase III trials. These include defining the precise contribution of chemotherapy by comparing induction chemotherapy and radiotherapy to treatment with radiotherapy alone; determining if elective neck dissection for patients with N2N3 neck disease would improve survival; and determining whether local control can be improved by using concomitant or alternating chemotherapy and radiotherapy.
Collapse
Affiliation(s)
- A A Forastiere
- Division of Medical Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
| |
Collapse
|
48
|
Westra WH, Forastiere AA, Eisele DW, Lee DJ. Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. Head Neck 1998; 20:515-21. [PMID: 9702538 DOI: 10.1002/(sici)1097-0347(199809)20:6<515::aid-hed5>3.0.co;2-j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND For patients with squamous cell carcinoma of the head and neck (HNSCC), persistence of cervical adenopathy following organ-preservation therapy is a strong predictor of locoregional failure. Squamous cell granulomas of the neck may represent a regressed state of metastatic HNSCC; however, relevant clinicopathologic features of this lesion including its morphologic characteristics, association with therapy, and relationship to disease progression are not well defined. METHODS We reviewed 866 consecutive neck dissections performed at The Johns Hopkins Hospital from 1984 to 1996. A total of eight cases showing a foreign-body giant-cell reaction to keratin in the absence of viable tumor formed the basis of this study. RESULTS All eight cases were from patients with stage III or IV HNSCC with concurrent neck masses. Patients were initially treated by chemotherapy (n = 1), radiotherapy (n = 1), or chemotherapy plus radiotherapy (n = 6); and all patients subsequently underwent neck dissection for persistence of their neck masses. Histologically, the neck lesions were characterized by a foreign-body giant-cell reaction to keratin and extensive scarring. None (0%) of the patients developed recurrent regional disease in the treated neck. Two (25%) of the patients had tumor recurrence at the primary site. Two (25%) of the patients developed widely metastatic disease. CONCLUSIONS These observations suggest that squamous cell granulomas represent histologic regression of metastatic squamous cell carcinoma in patients with HNSCC treated by chemotherapy and/or radiotherapy. Although persistent cervical adenopathy is an established risk factor for locoregional failure in this group of patients, squamous cell granulomas of the neck paradoxically may reflect enhanced regional tumor sensitivity to cytotoxic agents.
Collapse
Affiliation(s)
- W H Westra
- Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21287-6417, USA
| | | | | | | |
Collapse
|
49
|
Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998; 153:287-94. [PMID: 9665490 PMCID: PMC1852949 DOI: 10.1016/s0002-9440(10)65570-8] [Citation(s) in RCA: 100] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The incidence of esophageal adenocarcinoma has increased markedly in the past two decades, but the genetic alterations in this cancer and its precursor, Barrett mucosa, have not been characterized extensively. DNA replication errors and allelic losses of chromosomes 17p, 18q, and 5q were studied in 36 resected adenocarcinomas arising in the esophagus and esophagogastric junction, 56 Barrett adenocarcinomas, and 11 dysplasias in Barrett esophagus. The results were compared with clinical and pathological characteristics, including patient survival. Replication error positive cancer was rare (5.4%) in esophageal adenocarcinomas and was not found in Barrett mucosa. There was an increase in the prevalence of chromosomal losses in the Barrett mucosa-columnar dysplasia-adenocarcinoma sequence: 17p loss occurred in 14% of Barrett mucosae, 42% of low-grade dysplasias, 79% of high-grade dysplasias, and 75% of adenocarcinomas, respectively; loss of 18q in 32%, 42%, 73%, and 69%; and loss of 5q in 10%, 21%, 27%, and 46%. Clinical stage was a very strong prognostic factor for survival, and adenocarcinomas with allelic loss of both 17p and 18q had worse survival than cancers with no or one allelic loss (P = 0.002). Our results indicate that accumulation of genetic alterations follows the dysplasia-adenocarcinoma sequence in the esophagus and that losses of 18q and 17p occur earlier than 5q loss. Allelic loss of both 17p and 18q in esophageal adenocarcinoma identifies patients with poor prognosis.
Collapse
Affiliation(s)
- T T Wu
- Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA.
| | | | | | | | | | | |
Collapse
|
50
|
Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270-4. [PMID: 9610709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND A number of single agents have been tested in patients with carcinoma of the head and neck receiving palliative treatment. In general, 15-30% of patients achieve a partial response lasting 3-4 months. Treatment has not been shown to alter survival rates. It is clear that new drugs with potentially greater activity need to be identified. For this purpose, the Eastern Cooperative Oncology Group conducted a Phase II evaluation of paclitaxel. METHODS Patients with recurrent, metastatic, or locally advanced, incurable squamous cell carcinoma of the head and neck were eligible. The dose and schedule tested was the maximum tolerable dose of 250 mg/m2 determined from Phase I trials using a 24-hour infusion schedule and granulocyte-colony stimulating factor support. Courses were given at 3-week intervals until progression of disease was documented. Dose modifications were specified for hematologic toxicity and for neurotoxicity. RESULTS Thirty-four patients were registered on study and 30 were eligible. Severe or life-threatening granulocytopenia was the most frequent toxicity observed, occurring in 91% of patients. Prior to response evaluation, one patient died of sepsis and one died of a myocardial infarct. Response was observed in 40% of eligible patients (4 complete and 8 partial responses). The median duration of response was 4.5 months (range, 2-20 months), with a median survival of 9.2 months and a 1-year survival rate of 33%. CONCLUSIONS These results indicate that paclitaxel is an active agent for the treatment of squamous cell carcinoma of the head and neck. Studies evaluating alternative infusion schedules and combination regimens currently are underway.
Collapse
Affiliation(s)
- A A Forastiere
- Johns Hopkins Oncology Center, Baltimore, Maryland 21287-8936, USA
| | | | | | | | | | | |
Collapse
|